1. Home Page
  2. For Patients & Caregivers
  3. Learn About Cancers and Treatments
  4. Innovation at The James
  5. Clinical Trials
  6. Find a Clinical Trial
  7. A Phase I Openlabel Dose Escalation And Dose
All Clinical Trials

OSU-24220: ZE46-0134 Adlts FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Study Status Open To Accrual
National Clinical Trial Identifier NCT03013998
Phase I

  • A Phase I, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • If you are interested in participating in this study, call The JamesLine at 800-293-5066 to make an appointment with the principal investigator listed or ask your doctor if you are eligible for this study.

Trial Information

Protocol Number:OSU-24220
Gender:All
Disease Group:AML

Questions

If you are interested in participating in this study, call The JamesLine at 800-293-5066 to make an appointment with the principal investigator listed or ask your doctor if you are eligible for this study.